{name}
{subtitle}
Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)
city
~66 mi. (La Tronche, France, +25 more cities)
facility
CHU de Grenoble Hopital Nord ( Site 2027)
drug
coxsackievirus A21, +1 more drug
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~91 mi. (Valence, France, +137 more cities)
facility
Centre Hospitalier de Valence-Service de Dermatologie ( Site 0377)
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~97 mi. (Orbassano, Italy, +93 more cities)
facility
AOU San Luigi Gonzaga di Orbassano ( Site 0595)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types